Date: 2016-02-09
Type of information: Grant
Company: Westmead Institute’s Centre for Infectious Diseases and Microbiology (Australia) Ampliphi Biosciences (USA - VA)
Investors: Australian Government (Australia)
Amount: AUD $860,000 (€ 544 000 - $ 608 000)
Funding type: grant
Planned used: This grant will be used to isolate and develop phages that target E. Coli and Klebsiella. AmpliPhi Biosciences will participate in the project by providing its proprietary expertise in bacteriophage isolation, characterization and manufacturing scale-up. AmpliPhi’s Vice President of Research, Sandra Morales, is a Chief Investigator on the grant and will collaborate with lead investigator, Professor Jon Iredell from the Westmead Institute and Westmead Hospital in Sydney.
Others: * On February 9, 2016, AmpliPhi Biosciences announced that the Westmead Institute’s Centre for Infectious Diseases and Microbiology has won an AUD $860,000 grant from the Australian Government to isolate and develop phages that target two serious human pathogens, E. Coli and Klebsiella.
Therapeutic area: Infectious diseases
